Table 3.
The Relation between Age and CD4 Response and Virologic Suppression by 6- and 12-Months on Antiretroviral Therapy at Themba Lethu Clinic, Johannesburg, South Africa (n=9139)
| Failure to Achieve CD4 Count Response€ | 6-Months | 12-Months | ||||
|---|---|---|---|---|---|---|
| Failure to achieve CD4 response (n, %) |
Crude RR£ (95% CI) |
Adjusted† RR£ (95% CI) |
Failure to achieve CD4 response (n, %) |
Crude RR£ (95% CI) |
Adjusted† RR£ (95% CI) |
|
| Age (yrs.) | ||||||
| 18-29.9 | 223 (18.4) | 1.0 | 1.0 | 79 (8.0) | 1.0 | 1.0 |
| 30-39.9 | 671 (22.1) | 1.20 (1.04-1.37) | 1.14 (0.99-1.32) | 279 (11.2) | 1.39 (1.09-1.76) | 1.36 (1.06-1.743) |
| 40-49.9 | 393 (25.0) | 1.35 (1.17-1.56) | 1.23 (1.06-1.43) | 153 (11.2) | 1.50 (1.16-1.94) | 1.35 (1.03-1.78) |
| 50-59.9 | 150 (29.9) | 1.62 (1.35-1.94) | 1.43 (1.18-1.72) | 64 (15.1) | 1.96 (1.44-2.67) | 1.66 (1.20-2.29) |
| >60 | 27 (35.5) | 1.93 (1.39-2.67) | 1.44 (1.01-2.06) | 17 (27.9) | 3.49 (2.21-5.50) | 2.82 (1.78-4.46) |
| Baseline CD4 Count (cells/mm3) | ||||||
| 0-50 | 405 (18.7) | 1.0 | 1.0 | 86 (4.8) | 1.0 | 1.0 |
| 51-100 | 270 (20.6) | 1.10 (0.96-1.26) | 1.10 (0.96-1.27) | 109 (10.0) | 2.06 (1.57-2.71) | 2.13 (1.61-2.82) |
| 101-200 | 580 (27.0) | 1.45 (1.29-1.62) | 1.46 (1.31-1.64) | 296 (16.8) | 3.49 (2.76-4.39) | 3.76 (2.96-4.79) |
| 201-350 | 145 (33.5) | 1.79 (1.53-2.10) | 1.77 (1.50-2.09) | 72 (20.8) | 4.29 (3.21-5.74) | 4.67 (3.43-6.34) |
| Baseline Regimen | ||||||
| d4T-3TC-EFV | 1309 (22.9) | 1.0 | 1.0 | 545 (11.6) | 1.0 | 1.0 |
| d4T-3TC-NVP | 95 (19.5) | 0.85 (0.71-1.03) | 0.94 (0.77-1.13) | 27 (6.7) | 0.57 (0.39-0.83) | 0.66 (0.46-0.96) |
| AZT-3TC-NVP / EFV | 60 (31.3) | 1.37 (1.10-1.70) | 1.22 (0.98-1.51) | 20 (12.6) | 1.08 (0.71-1.64) | 0.92 (0.60-1.41) |
| Failure to Achieve Viral Load Suppression¥ | 6-Months | 12-Months | ||||
|---|---|---|---|---|---|---|
| Failure to achieve viral load suppression (n, %) |
Crude RR£ (95% CI) |
Adjusted† RR£ (95% CI) |
Failure to achieve viral load suppression (n, %) |
Crude RR£ (95% CI) |
Adjusted† RR£ (95% CI) |
|
| Age (yrs.) | ||||||
| 18-29.9 | 122 (10.7) | 1.0 | 1.0 | 86 (9.6) | 1.0 | 1.0 |
| 30-39.9 | 256 (9.1) | 0.85 (0.69-1.04) | 0.87 (0.70-1.09) | 204 (8.9) | 0.92 (0.72-1.17) | 0.93 (0.72-1.20) |
| 40-49.9 | 122 (8.1) | 0.76 (0.60-0.96) | 0.75 (0.58-0.98) | 109 (9.6) | 1.00 (0.76-1.30) | 0.90 (0.67-1.21) |
| 50-59.9 | 36 (7.7) | 0.71 (0.50-1.02) | 0.80 (0.55-1.17) | 34 (9.4) | 0.98 (0.67-1.43) | 1.06 (0.71-1.58) |
| >60 | 6 (8.7) | 0.81 (0.37-1.77) | 0.99 (0.45-2.17) | 3 (5.8) | 0.60 (0.20-1.83) | 0.67 (0.22-2.05) |
| Baseline CD4 Count (cells/mm3) | ||||||
| 0-50 | 182 (9.2) | 1.0 | 1.0 | 151 (9.8) | 1.0 | 1.0 |
| 51-100 | 103 (8.7) | 0.95 (0.76-1.20) | 0.94 (0.74-1.19) | 90 (9.8) | 1.00 (0.78-1.28) | 1.01 (0.79-1.04) |
| 101-200 | 171 (8.8) | 0.96 (0.79-1.17) | 0.96 (0.78-1.18) | 123 (8.0) | 0.82 (0.65-1.02) | 0.82 (0.65-1.32) |
| 201-350 | 25 (6.6) | 0.72 (0.48-1.07) | 0.75 (0.50-1.13) | 24 (7.9) | 0.81 (0.53-1.22) | 0.86 (0.57-1.30) |
| Baseline Regimen | ||||||
| d4T-3TC-EFV | 464 (8.7) | 1.0 | 1.0 | 371 (8.8) | 1.0 | 1.0 |
| d4T-3TC-NVP | 55 (12.1) | 1.40 (1.08-1.82) | 1.42 (1.06-1.89) | 50 (13.7) | 1.56 (1.19-2.06) | 1.53 (1.21-2.10) |
| AZT-3TC-NVP / | 23 (12.9) | 1.48 (1.00-2.19) | 1.34 (0.85-2.12) | 15 (10.5) | 1.20 (0.74-1.95) | 1.10 (0.64-1.92) |
| AZT-3TC-EFV | ||||||
£
Relative risk (RR) estimated from a log-binomial regression model
†
Models adjusted for sex, baseline haemoglobin, baseline WHO stage and baseline BMI
€
Failure to achieve a CD4 response defined as an increase of ≥50 cells/mm3
¥
Failure to achieve VL suppression defined as not reaching a viral load <400 copies/ml VL, viral load; CI, confidence interval